Published in PLoS One on September 14, 2011
Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo. Nat Commun (2013) 1.66
A mechanistic compartmental model for total antibody uptake in tumors. J Theor Biol (2012) 1.07
Current advances in mathematical modeling of anti-cancer drug penetration into tumor tissues. Front Oncol (2013) 1.05
Efficient (18)F-Labeling of Synthetic Exendin-4 Analogues for Imaging Beta Cells. ChemistryOpen (2012) 1.00
Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer (2016) 0.99
Effect of small-molecule modification on single-cell pharmacokinetics of PARP inhibitors. Mol Cancer Ther (2014) 0.98
Vaginal delivery of paclitaxel via nanoparticles with non-mucoadhesive surfaces suppresses cervical tumor growth. Adv Healthc Mater (2013) 0.95
Bacterial delivery of Staphylococcus aureus α-hemolysin causes regression and necrosis in murine tumors. Mol Ther (2014) 0.90
Quantitative in vivo cell-surface receptor imaging in oncology: kinetic modeling and paired-agent principles from nuclear medicine and optical imaging. Phys Med Biol (2015) 0.85
Single cell analysis of drug distribution by intravital imaging. PLoS One (2013) 0.85
Serial diffusion MRI to monitor and model treatment response of the targeted nanotherapy CRLX101. Clin Cancer Res (2013) 0.85
Enhancement of Immune Effector Functions by Modulating IgG's Intrinsic Affinity for Target Antigen. PLoS One (2016) 0.84
Residualization Rates of Near-Infrared Dyes for the Rational Design of Molecular Imaging Agents. Mol Imaging Biol (2015) 0.82
Multichannel imaging to quantify four classes of pharmacokinetic distribution in tumors. J Pharm Sci (2014) 0.82
Quantitative Impact of Plasma Clearance and Down-regulation on GLP-1 Receptor Molecular Imaging. Mol Imaging Biol (2016) 0.81
Quorum-sensing Salmonella selectively trigger protein expression within tumors. Proc Natl Acad Sci U S A (2015) 0.80
A mechanistic tumor penetration model to guide antibody drug conjugate design. PLoS One (2015) 0.80
A computational framework for identifying design guidelines to increase the penetration of targeted nanoparticles into tumors. Nano Today (2013) 0.80
Mathematical and computational models of drug transport in tumours. J R Soc Interface (2014) 0.78
Tailoring Adjuvant Radiation Therapy by Intraoperative Imaging to Detect Residual Cancer. Semin Radiat Oncol (2015) 0.78
Endothelial Thermotolerance Impairs Nanoparticle Transport in Tumors. Cancer Res (2015) 0.78
Mechanisms of cooperation in cancer nanomedicine: towards systems nanotechnology. Trends Biotechnol (2014) 0.78
Mechanistic and quantitative insight into cell surface targeted molecular imaging agent design. Sci Rep (2016) 0.78
Towards an integrated systems-based modelling framework for drug transport and its effect on tumour cells. J Biol Eng (2014) 0.77
Advances in measuring single-cell pharmacology in vivo. Drug Discov Today (2015) 0.76
Combination Radioimmunotherapy Approaches and Quantification of Immuno-PET. Nucl Med Mol Imaging (2016) 0.76
Quantifying and Reducing Uncertainties in Cancer Therapy. Proc SPIE Int Soc Opt Eng (2015) 0.76
Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy. AAPS J (2016) 0.76
Spatial frequency analysis of anisotropic drug transport in tumor samples. J Biomed Opt (2014) 0.75
Spatial Modeling of Drug Delivery Routes for Treatment of Disseminated Ovarian Cancer. Cancer Res (2015) 0.75
Therapy operating characteristic curves: tools for precision chemotherapy. J Med Imaging (Bellingham) (2016) 0.75
Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging. Nat Commun (2017) 0.75
Drug delivery in a tumour cord model: a computational simulation. R Soc Open Sci (2017) 0.75
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 23.44
Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging (1999) 13.26
Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res (1989) 12.85
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med (2009) 11.63
Drug penetration in solid tumours. Nat Rev Cancer (2006) 9.80
Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab (1983) 9.59
Cell and environment interactions in tumor microregions: the multicell spheroid model. Science (1988) 6.02
Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol (2005) 5.80
A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol (2008) 5.56
Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng (1999) 3.64
Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res (1988) 3.37
Microvascular permeability of normal and neoplastic tissues. Microvasc Res (1986) 3.04
Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc Natl Acad Sci U S A (2001) 2.96
Intermittent blood flow in a murine tumor: radiobiological effects. Cancer Res (1987) 2.85
Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol (2005) 2.55
Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer (2003) 2.40
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther (2009) 2.36
Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev (2008) 2.16
Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res (2002) 2.05
Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors. Cancer Res (1989) 2.04
The shunt problem: control of functional shunting in normal and tumour vasculature. Nat Rev Cancer (2010) 1.97
Methotrexate pharmacokinetics. J Pharm Sci (1971) 1.94
Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys (2005) 1.89
A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med (1990) 1.85
Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn (2007) 1.82
Spatial heterogeneity and oxygen dependence of glucose consumption in R3230Ac and fibrosarcomas of the Fischer 344 rat. Cancer Res (2005) 1.81
Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med (2007) 1.69
Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res (1998) 1.68
Live imaging of cysteine-cathepsin activity reveals dynamics of focal inflammation, angiogenesis, and polyp growth. PLoS One (2008) 1.55
Transport of fluid and macromolecules in tumors. II. Role of heterogeneous perfusion and lymphatics. Microvasc Res (1990) 1.54
Innovation: Rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nat Rev Drug Discov (2005) 1.52
Green's function methods for analysis of oxygen delivery to tissue by microvascular networks. Ann Biomed Eng (2004) 1.52
Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res (1994) 1.45
Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci (2002) 1.44
Role of tumor vascular architecture in nutrient and drug delivery: an invasion percolation-based network model. Microvasc Res (1996) 1.43
Noninvasive measurement of microvascular and interstitial oxygen profiles in a human tumor in SCID mice. Proc Natl Acad Sci U S A (1994) 1.36
Quantitative techniques in 18FDG PET scanning in oncology. Br J Cancer (2008) 1.33
Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Res (1999) 1.31
Review of methods used to study oxygen transport at the microcirculatory level. Int J Cancer (2000) 1.27
Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. Eur J Nucl Med Mol Imaging (2008) 1.26
Red blood cells: a neglected compartment in pharmacokinetics and pharmacodynamics. Pharmacol Rev (1997) 1.24
Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids. Cancer Res (2008) 1.24
Theoretical models of microvascular oxygen transport to tissue. Microcirculation (2008) 1.17
Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells. Cancer (1994) 1.09
Tumor blood flow measured by PET dynamic imaging of first-pass 18F-FDG uptake: a comparison with 15O-labeled water-measured blood flow. J Nucl Med (2008) 1.08
Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model. Radiology (2008) 1.04
A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments. Mol Cancer Ther (2006) 1.03
Quantitating antibody uptake in vivo: conditional dependence on antigen expression levels. Mol Imaging Biol (2011) 1.03
The rate-limiting step for tumor [18F]fluoro-2-deoxy-D-glucose (FDG) incorporation. Nucl Med Biol (2001) 1.01
Next-generation model-based drug discovery and development: quantitative and systems pharmacology. Clin Pharmacol Ther (2010) 0.99
Diffusion-limited binding explains binary dose response for local arterial and tumour drug delivery. Cell Prolif (2009) 0.99
Multicolor fluorescent intravital live microscopy (FILM) for surgical tumor resection in a mouse xenograft model. PLoS One (2009) 0.99
Calculations of intracapillary oxygen tension distributions in muscle. Math Biosci (2000) 0.98
Cellular membrane permeability of anthracyclines does not correlate with their delivery in a tissue-isolated tumor. Cancer Res (1999) 0.93
Numerical simulation of oxygen delivery to muscle tissue in the presence of hemoglobin-based oxygen carriers. Biotechnol Prog (2006) 0.90
Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotin. Clin Cancer Res (2004) 0.84
Relationship between tumour morphology, antigen and antibody distribution measured by fusion of digital phosphor and photographic images. Cancer Immunol Immunother (2001) 0.84
Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. Eur J Nucl Med Mol Imaging (2010) 0.84
Capillary supply regions. Math Biosci (2001) 0.83
PK/PD modelling and beyond: impact on drug development. Pharm Res (2008) 0.82
Heterogeneity in antigenic expression and radiosensitivity in human colon carcinoma cell lines. In Vitro Cell Dev Biol (1991) 0.79
Quantitative relationship between the octanol/water partition coefficient and the diffusion limitation of the exchange between adipose and blood. BMC Clin Pharmacol (2010) 0.79
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
Restoration of p53 function leads to tumour regression in vivo. Nature (2007) 12.62
The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med (2007) 11.51
Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science (2009) 10.47
Looking and listening to light: the evolution of whole-body photonic imaging. Nat Biotechnol (2005) 9.57
Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med (2003) 9.09
Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest (2007) 8.65
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell (2012) 7.36
Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur Radiol (2002) 6.06
Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol Ther (2005) 6.04
Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A (2006) 5.90
Fluorescence molecular tomography resolves protease activity in vivo. Nat Med (2002) 5.53
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell (2006) 5.34
Arthritis critically dependent on innate immune system players. Immunity (2002) 5.31
Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell (2002) 5.11
The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell (2010) 5.11
Myocardial infarction accelerates atherosclerosis. Nature (2012) 4.48
Chip-NMR biosensor for detection and molecular analysis of cells. Nat Med (2008) 4.29
Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation (2007) 4.20
Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med (2013) 4.14
Magnetic relaxation switches capable of sensing molecular interactions. Nat Biotechnol (2002) 4.13
Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci U S A (2004) 4.12
Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med (2012) 4.11
A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med (2007) 3.96
Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol (2011) 3.95
Tetrazine-based cycloadditions: application to pretargeted live cell imaging. Bioconjug Chem (2008) 3.93
Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. Immunity (2006) 3.92
Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation (2007) 3.85
Fast and sensitive pretargeted labeling of cancer cells through a tetrazine/trans-cyclooctene cycloaddition. Angew Chem Int Ed Engl (2009) 3.63
Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation (2006) 3.57
Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation (2007) 3.51
Molecular imaging in drug discovery and development. Nat Rev Drug Discov (2003) 3.44
Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. Proc Natl Acad Sci U S A (2006) 3.38
Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv Drug Deliv Rev (2008) 3.34
A secreted luciferase for ex vivo monitoring of in vivo processes. Nat Methods (2008) 3.31
Intravital imaging. Cell (2011) 3.18
Rapid monocyte kinetics in acute myocardial infarction are sustained by extramedullary monocytopoiesis. J Exp Med (2012) 2.92
Multivalent effects of RGD peptides obtained by nanoparticle display. J Med Chem (2006) 2.91
MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Res (2007) 2.90
Impaired infarct healing in atherosclerotic mice with Ly-6C(hi) monocytosis. J Am Coll Cardiol (2010) 2.90
Near-infrared fluorescence: application to in vivo molecular imaging. Curr Opin Chem Biol (2009) 2.89
An X-ray computed tomography imaging agent based on long-circulating bismuth sulphide nanoparticles. Nat Mater (2006) 2.84
Ultrasensitive clinical enumeration of rare cells ex vivo using a micro-hall detector. Sci Transl Med (2012) 2.82
The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell (2012) 2.78
Dual channel optical tomographic imaging of leukocyte recruitment and protease activity in the healing myocardial infarct. Circ Res (2007) 2.77
Visualization of antitumor treatment by means of fluorescence molecular tomography with an annexin V-Cy5.5 conjugate. Proc Natl Acad Sci U S A (2004) 2.77
Rapid detection and profiling of cancer cells in fine-needle aspirates. Proc Natl Acad Sci U S A (2009) 2.75
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A (2006) 2.72
Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ Res (2005) 2.67
Detection of dysplastic intestinal adenomas using enzyme-sensing molecular beacons in mice. Gastroenterology (2002) 2.64
In vivo imaging of proteolytic activity in atherosclerosis. Circulation (2002) 2.62
Molecular imaging in the clinical arena. JAMA (2005) 2.59
A submillimeter resolution fluorescence molecular imaging system for small animal imaging. Med Phys (2003) 2.58
Focal disruption of the blood-brain barrier due to 260-kHz ultrasound bursts: a method for molecular imaging and targeted drug delivery. J Neurosurg (2006) 2.58
miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell (2008) 2.57
Bioorthogonal turn-on probes for imaging small molecules inside living cells. Angew Chem Int Ed Engl (2010) 2.57
Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation (2006) 2.56
A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res (2003) 2.55
Real-time catheter molecular sensing of inflammation in proteolytically active atherosclerosis. Circulation (2008) 2.52
Bioorthogonal chemistry amplifies nanoparticle binding and enhances the sensitivity of cell detection. Nat Nanotechnol (2010) 2.49
One-Pot Synthesis of New Symmetric and Asymmetric Xanthene Dyes. Tetrahedron Lett (2007) 2.49
Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci U S A (2009) 2.47
Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst (2007) 2.46
Near-infrared fluorescent imaging of matrix metalloproteinase activity after myocardial infarction. Circulation (2005) 2.45
Near-infrared fluorescent nanoparticles as combined MR/optical imaging probes. Bioconjug Chem (2002) 2.45
Extramedullary hematopoiesis generates Ly-6C(high) monocytes that infiltrate atherosclerotic lesions. Circulation (2011) 2.45
Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci U S A (2012) 2.42
PET/MRI of inflammation in myocardial infarction. J Am Coll Cardiol (2012) 2.39
Identification of the target self-antigens in reperfusion injury. J Exp Med (2006) 2.38
Molecular imaging of cardiovascular disease. Circulation (2007) 2.33
Colonic adenocarcinomas: near-infrared microcatheter imaging of smart probes for early detection--study in mice. Radiology (2007) 2.29
PepBank--a database of peptides based on sequence text mining and public peptide data sources. BMC Bioinformatics (2007) 2.27
Quantitative real-time catheter-based fluorescence molecular imaging in mice. Radiology (2007) 2.26
Optical visualization of cathepsin K activity in atherosclerosis with a novel, protease-activatable fluorescence sensor. Circulation (2007) 2.20
Fluorescence tomography and magnetic resonance imaging of myocardial macrophage infiltration in infarcted myocardium in vivo. Circulation (2007) 2.19
18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis. JACC Cardiovasc Imaging (2009) 2.17
Hybrid PET-optical imaging using targeted probes. Proc Natl Acad Sci U S A (2010) 2.17
Volumetric tomography of fluorescent proteins through small animals in vivo. Proc Natl Acad Sci U S A (2005) 2.16
Hybrid in vivo FMT-CT imaging of protease activity in atherosclerosis with customized nanosensors. Arterioscler Thromb Vasc Biol (2009) 2.15
Particularities of the vasculature can promote the organ specificity of autoimmune attack. Nat Immunol (2006) 2.12
In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors. Cancer Res (2003) 2.12
Early window of diabetes determinism in NOD mice, dependent on the complement receptor CRIg, identified by noninvasive imaging. Nat Immunol (2012) 2.11
Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc Natl Acad Sci U S A (2009) 2.11
Biomedical applications of tetrazine cycloadditions. Acc Chem Res (2011) 2.10
Innate response activator B cells protect against microbial sepsis. Science (2012) 2.07
Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease. Circulation (2009) 2.07
Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Med (2008) 2.06
Perturbational profiling of nanomaterial biologic activity. Proc Natl Acad Sci U S A (2008) 2.04
Magnetic resonance imaging of cardiomyocyte apoptosis with a novel magneto-optical nanoparticle. Magn Reson Med (2005) 2.03
Near-infrared optical imaging of proteases in cancer. Mol Cancer Ther (2003) 2.02
Mast cells are an essential hematopoietic component for polyp development. Proc Natl Acad Sci U S A (2007) 2.02
Catheter-based in vivo imaging of enzyme activity and gene expression: feasibility study in mice. Radiology (2004) 2.01
WNT5A/JNK and FGF/MAPK pathways regulate the cellular events shaping the vertebrate limb bud. Curr Biol (2010) 2.00
Early photon tomography allows fluorescence detection of lung carcinomas and disease progression in mice in vivo. Proc Natl Acad Sci U S A (2008) 2.00
Analysis of mitosis and antimitotic drug responses in tumors by in vivo microscopy and single-cell pharmacodynamics. Cancer Res (2011) 1.99
The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res (2005) 1.97
Activatable magnetic resonance imaging agent reports myeloperoxidase activity in healing infarcts and noninvasively detects the antiinflammatory effects of atorvastatin on ischemia-reperfusion injury. Circulation (2008) 1.97
Micro-NMR for rapid molecular analysis of human tumor samples. Sci Transl Med (2011) 1.96
Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients. J Clin Invest (2010) 1.93
Dextran-coated iron oxide nanoparticles: a versatile platform for targeted molecular imaging, molecular diagnostics, and therapy. Acc Chem Res (2011) 1.93